gleevec® (imatinib mesylate) advancing the treatment of ph+ chronic myeloid leukemia (cml) doug...
TRANSCRIPT
![Page 1: Gleevec® (imatinib mesylate) Advancing the Treatment of Ph+ Chronic Myeloid Leukemia (CML) Doug Brutlag Professor Emeritus of Biochemistry and Medicine](https://reader035.vdocuments.us/reader035/viewer/2022062516/56649e685503460f94b65373/html5/thumbnails/1.jpg)
Gleevec®(imatinib mesylate)
Advancing the Treatment of Ph+
Chronic Myeloid Leukemia (CML)Doug Brutlag
Professor Emeritus of Biochemistry and [email protected]
![Page 2: Gleevec® (imatinib mesylate) Advancing the Treatment of Ph+ Chronic Myeloid Leukemia (CML) Doug Brutlag Professor Emeritus of Biochemistry and Medicine](https://reader035.vdocuments.us/reader035/viewer/2022062516/56649e685503460f94b65373/html5/thumbnails/2.jpg)
CML: a Progressive and Fatal Disease
![Page 3: Gleevec® (imatinib mesylate) Advancing the Treatment of Ph+ Chronic Myeloid Leukemia (CML) Doug Brutlag Professor Emeritus of Biochemistry and Medicine](https://reader035.vdocuments.us/reader035/viewer/2022062516/56649e685503460f94b65373/html5/thumbnails/3.jpg)
CML: Linked to a Single Molecular Abnormality
![Page 4: Gleevec® (imatinib mesylate) Advancing the Treatment of Ph+ Chronic Myeloid Leukemia (CML) Doug Brutlag Professor Emeritus of Biochemistry and Medicine](https://reader035.vdocuments.us/reader035/viewer/2022062516/56649e685503460f94b65373/html5/thumbnails/4.jpg)
Gleevec® Targets the Cause of CML
![Page 5: Gleevec® (imatinib mesylate) Advancing the Treatment of Ph+ Chronic Myeloid Leukemia (CML) Doug Brutlag Professor Emeritus of Biochemistry and Medicine](https://reader035.vdocuments.us/reader035/viewer/2022062516/56649e685503460f94b65373/html5/thumbnails/5.jpg)
Inhibition of Cellular Proliferation by Gleevechttp://www.biocarta.com/pathfiles/h_gleevecpathway.asp
![Page 6: Gleevec® (imatinib mesylate) Advancing the Treatment of Ph+ Chronic Myeloid Leukemia (CML) Doug Brutlag Professor Emeritus of Biochemistry and Medicine](https://reader035.vdocuments.us/reader035/viewer/2022062516/56649e685503460f94b65373/html5/thumbnails/6.jpg)
CML: Its Cause and Management
![Page 7: Gleevec® (imatinib mesylate) Advancing the Treatment of Ph+ Chronic Myeloid Leukemia (CML) Doug Brutlag Professor Emeritus of Biochemistry and Medicine](https://reader035.vdocuments.us/reader035/viewer/2022062516/56649e685503460f94b65373/html5/thumbnails/7.jpg)
Gleevec®: Pharmacokinetics
![Page 8: Gleevec® (imatinib mesylate) Advancing the Treatment of Ph+ Chronic Myeloid Leukemia (CML) Doug Brutlag Professor Emeritus of Biochemistry and Medicine](https://reader035.vdocuments.us/reader035/viewer/2022062516/56649e685503460f94b65373/html5/thumbnails/8.jpg)
Phase I Study: Gleevec® Achieves Hematologic and Cytogenetic
Responses
![Page 9: Gleevec® (imatinib mesylate) Advancing the Treatment of Ph+ Chronic Myeloid Leukemia (CML) Doug Brutlag Professor Emeritus of Biochemistry and Medicine](https://reader035.vdocuments.us/reader035/viewer/2022062516/56649e685503460f94b65373/html5/thumbnails/9.jpg)
Phase II Results: Highest Response Rates in Chronic Phase
![Page 10: Gleevec® (imatinib mesylate) Advancing the Treatment of Ph+ Chronic Myeloid Leukemia (CML) Doug Brutlag Professor Emeritus of Biochemistry and Medicine](https://reader035.vdocuments.us/reader035/viewer/2022062516/56649e685503460f94b65373/html5/thumbnails/10.jpg)
Higher Dose: Longer Time to Disease Progression
![Page 11: Gleevec® (imatinib mesylate) Advancing the Treatment of Ph+ Chronic Myeloid Leukemia (CML) Doug Brutlag Professor Emeritus of Biochemistry and Medicine](https://reader035.vdocuments.us/reader035/viewer/2022062516/56649e685503460f94b65373/html5/thumbnails/11.jpg)
IRIS Study: Reevaluating First-Line CML Therapy
![Page 12: Gleevec® (imatinib mesylate) Advancing the Treatment of Ph+ Chronic Myeloid Leukemia (CML) Doug Brutlag Professor Emeritus of Biochemistry and Medicine](https://reader035.vdocuments.us/reader035/viewer/2022062516/56649e685503460f94b65373/html5/thumbnails/12.jpg)
IRIS: The Largest Phase III CML Study to Date
![Page 13: Gleevec® (imatinib mesylate) Advancing the Treatment of Ph+ Chronic Myeloid Leukemia (CML) Doug Brutlag Professor Emeritus of Biochemistry and Medicine](https://reader035.vdocuments.us/reader035/viewer/2022062516/56649e685503460f94b65373/html5/thumbnails/13.jpg)
Longer Time to Progression With Gleevec®
![Page 14: Gleevec® (imatinib mesylate) Advancing the Treatment of Ph+ Chronic Myeloid Leukemia (CML) Doug Brutlag Professor Emeritus of Biochemistry and Medicine](https://reader035.vdocuments.us/reader035/viewer/2022062516/56649e685503460f94b65373/html5/thumbnails/14.jpg)
Higher Cytogenetic Response Rates With Gleevec®
![Page 15: Gleevec® (imatinib mesylate) Advancing the Treatment of Ph+ Chronic Myeloid Leukemia (CML) Doug Brutlag Professor Emeritus of Biochemistry and Medicine](https://reader035.vdocuments.us/reader035/viewer/2022062516/56649e685503460f94b65373/html5/thumbnails/15.jpg)
Early Responses in More Patients With Gleevec®
![Page 16: Gleevec® (imatinib mesylate) Advancing the Treatment of Ph+ Chronic Myeloid Leukemia (CML) Doug Brutlag Professor Emeritus of Biochemistry and Medicine](https://reader035.vdocuments.us/reader035/viewer/2022062516/56649e685503460f94b65373/html5/thumbnails/16.jpg)
More Patients Remain on Gleevec® Therapy
![Page 17: Gleevec® (imatinib mesylate) Advancing the Treatment of Ph+ Chronic Myeloid Leukemia (CML) Doug Brutlag Professor Emeritus of Biochemistry and Medicine](https://reader035.vdocuments.us/reader035/viewer/2022062516/56649e685503460f94b65373/html5/thumbnails/17.jpg)
Most Non-Hematologic Adverse Events Less Common With Gleevec®
![Page 18: Gleevec® (imatinib mesylate) Advancing the Treatment of Ph+ Chronic Myeloid Leukemia (CML) Doug Brutlag Professor Emeritus of Biochemistry and Medicine](https://reader035.vdocuments.us/reader035/viewer/2022062516/56649e685503460f94b65373/html5/thumbnails/18.jpg)
Fewer Hematologic Adverse Events With Gleevec®
![Page 19: Gleevec® (imatinib mesylate) Advancing the Treatment of Ph+ Chronic Myeloid Leukemia (CML) Doug Brutlag Professor Emeritus of Biochemistry and Medicine](https://reader035.vdocuments.us/reader035/viewer/2022062516/56649e685503460f94b65373/html5/thumbnails/19.jpg)
Massive Protein Kinase Database
• Abbott Labs Publishes Massive Protein Kinase Dataset, New Statistical Method to Analyze Kinome
• March 11, 2011
• By Adam Bonislawski
• Scientists from Abbott Laboratories' pharmaceutical-discovery division have released kinomics screening data about how 3,800 different inhibitors affect 172 protein kinases.
• In a study published last month in the online edition of Nature Chemical Biology, the researchers showed how they tried to group these kinases based on both sequence and pharmacological relationships and by their interactions with various inhibitor chemoty